(9ci)-1-氨基-2,3-二氢-5-羟基-1H-茚-2-羧酸 | 302838-25-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (9ci)-1-氨基-2,3-二氢-5-羟基-1H-茚-2-羧酸
• 英文名称: 1-Amino-5-hydroxy-2,3-dihydro-1H-indene-2-carboxylic acid
• CAS: 302838-25-1
• 化学式: C₁₀H₁₁NO₃
• 分子量: 193.2
• InChiKey: LELXPXFAAIPMKW-UHFFFAOYSA-N

物化性质

• 沸点：
  450.2±45.0 °C(Predicted)
• 密度：
  1.412±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.7
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  83.6
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• ISO CA-4 AND ANALOGUES THEREOF AS POTENT CYTOTOXIC AGENTS INHIBITING TUBULINE POLYMERIZATION
  申请人：Alami Mouâd

  公开号：US20100129471A1

  公开（公告）日：2010-05-27

  The invention relates to a compound of the formula (I) in which: R 1 , R 2 and R 3 are independently a methoxy group optionally substituted by one or more fluorine atoms; R 4 is a hydrogen atom; R 5 and R 6 are identical and each represent a hydrogen or fluorine atom; A is a cycle selected from the group including aryl and heteroaryl groups, wherein said groups can be substituted.

  这项发明涉及公式（I）的化合物，其中：R1、R2和R3分别是一个甲氧基基团，该基团可以选择性地被一个或多个氟原子取代；R4是一个氢原子；R5和R6相同，每个代表一个氢或氟原子；A是从包括芳基和杂环基团在内的一组环中选择的，其中这些基团可以被取代。
• DIHYDRO-ISO-CA-4 AND ANALOGUES: POTENT CYTOTOXICS, INHIBITORS OF TUBULIN POLYMERIZATION
  申请人：Alami Mouâd

  公开号：US20110160228A1

  公开（公告）日：2011-06-30

  The present invention relates to compounds of formula (I) below in which: —R 1 and R 3 represent, independently of one another, a methoxy group optionally substituted by one or more fluorine atoms, —R 2 and R 4 represent, independently of one another, a hydrogen atom or a methoxy group optionally substituted by one or more fluorine atoms, —A represents a ring chosen from the group comprising aryl and heteroaryl groups, said ring possibly being substituted by or fused to a heterocycle, —X represents a nitrogen atom or a CH group, and —Z 1 represents a hydrogen atom or a halogen atom, preferably fluorine, and —Z 2 represents a hydrogen atom, a halogen atom, preferably fluorine, a C 1 to C 4 alkyl group, an aryl group or a —CN, —SO 2 NR 12 R 13 , —SO 2 R 9 , —COOR 15 or —COR 15 group, and also to the pharmaceutically acceptable salts thereof, the isomers thereof and the prodrugs thereof.

  本发明涉及以下式（I）的化合物，其中：-R1和R3分别独立地表示一个甲氧基，该甲氧基可以被一个或多个氟原子取代，-R2和R4分别独立地表示一个氢原子或一个甲氧基，该甲氧基可以被一个或多个氟原子取代，-A表示从含有芳基和杂环芳基的群中选择的一个环，该环可能被一个杂环取代或融合，-X表示一个氮原子或一个CH基团，-Z1表示一个氢原子或一个卤原子，优选氟，-Z2表示一个氢原子，一个卤原子，优选氟，一个C1到C4烷基，一个芳基或一个-CN，-SO2NR12R13，-SO2R9，-COOR15或-COR15基团，以及其在药学上可接受的盐，其异构体和其前药。
• Method for synthesizing peptides comprising at least one glycine molecule
  申请人：——

  公开号：US20040077830A1

  公开（公告）日：2004-04-22

  Method for preparing a peptide or a peptide derivative comprising at least 2 enantiopure amino acids and at least one glycine molecule, comprising the reaction of a compound of general formula XCH 2 —C(═O)—HN—A—COOY (II) with a compound of general formula HNR 1 R 2 (III).

  制备含有至少2个对映纯氨基酸和至少一个甘氨酸分子的肽或肽衍生物的方法，包括将一般式XCH2—C(═O)—HN—A—COOY (II)的化合物与一般式HNR1R2(III)的化合物进行反应。
• Process for the separation of enantiomers and enantiopure reagent
  申请人：SOLVAY S.A.

  公开号：US20040210060A1

  公开（公告）日：2004-10-21

  Process for the separation of enantiomers comprising at least one free functional group, in which process a reagent based on an enantiopure amino acid is reacted in basic medium with a mixture comprising enantiomers.

  分离具有至少一个自由官能团的对映体的过程，其中使用基于对映纯氨基酸的试剂在碱性介质中与含有对映体混合物反应。
• Process for the manufacture of persilylated peptides
  申请人：SOLVAY (Société Anonyme)

  公开号：EP2060580A1

  公开（公告）日：2009-05-20

  Process for the manufacture of a peptide or peptide analog, which comprises (a) producing a persilylated peptide or persilylated peptide analogue by silylating a corresponding peptide by reaction with a silylating agent other than trimethylsilylcyanide and (b) reacting a compound of formula (I) X-A-COOH wherein X is an amino protecting group, A is an aminoacid, peptide or peptide analogue residue and -COOH designates an optionally activated carboxylic group, with a persilylated peptide or a persilylated peptide analogue containing from 4 to 15 aminoacids.

  制备肽或肽类似物的过程，包括(a)通过与非三甲基硅氰基以外的硅化试剂反应，硅化相应的肽，制备硅醚化的肽或硅醚化的肽类似物，以及(b)将式(I)的化合物X-A-COOH与含有4至15个氨基酸的硅醚化的肽或硅醚化的肽类似物反应，其中X是氨基保护基，A是氨基酸、肽或肽类似物残基，-COOH表示可选择激活的羧基。